MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy

Cancer Letters

Volumn 329, Issue 1, 2013, Pages 91-98

  Zhang, Jia Xing ^a   Qian, Dong ^a   Wang, Feng Wei ^a   Liao, Ding Zhun ^a   Wei, Jin Huan ^a,b   Tong, Zhu Ting ^a,c   Fu, Jia ^a   Huang, Xiao Xia ^a   Liao, Yi Ji ^a   Deng, Hai Xia ^a   Zeng, Yi Xin ^a   Xie, Dan ^a   Mai, Shi Juan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Chemosensitivity; MicroRNA 29c; Nasopharyngeal carcinoma; Radiosensitivity

Indexed keywords

CISPLATIN; MICRORNA 29; MICRORNA 29C; PROTEIN BCL 2; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION, IONIZING; TREATMENT OUTCOME;

EID: 84871714536     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.033     Document Type: Article

References (37)

1. Wei W.I., Sham J.S. Nasopharyngeal carcinoma. Lancet 2005, 365:2041-2054.
2. Cao S.M., Simons M.J., Qian C.N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chinese J. Cancer 2011, 30:114-119.
3. Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin. Cancer Biol. 2002, 12:421-429.
4. Chan A.T. Current treatment of nasopharyngeal carcinoma. Eur. J. Cancer 2011, 47(Suppl 3):S302-S303.
5. Chen Q.Y., Wen Y.F., Guo L., Liu H., Huang P.Y., Mo H.Y., et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J. Natl Cancer Inst. 2011, 103:1761-1770.
6. Jia W.H., Huang Q.H., Liao J., Ye W., Shugart Y.Y., Liu Q., et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer 2006, 6:178.
7. Portugal J., Bataller M., Mansilla S. Cell death pathways in response to antitumor therapy. Tumori 2009, 95:409-421.
8. Lin J.C., Chen K.Y., Jan J.S., Hsu C.Y. Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36:1127-1136.
9. Cai M.Y., Tong Z.T., Zhu W., Wen Z.Z., Rao H.L., Kong L.L., et al. H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma. Mol. Med. 2011.
10. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
11. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
12. Valencia-Sanchez M.A., Liu J., Hannon G.J., Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006, 20:515-524.
13. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
14. Kloosterman W.P., Plasterk R.H. The diverse functions of microRNAs in animal development and disease. Dev. Cell 2006, 1:441-450.
15. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
16. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
17. Mraz M., Malinova K., Kotaskova J., Pavlova S., Tichy B., Malcikova J., et al. MiR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 2009, 23:1159-1163.
18. Ding D.P., Chen Z.L., Zhao X.H., Wang J.W., Sun J., Wang Z., et al. MiR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression. Carcinogenesis 2011, 32:1025-1032.
19. Wang C.M., Wang Y., Fan C.G., Xu F.F., Sun W.S., Liu Y.G., et al. MiR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2011, 411:586-592.
20. Chen H.C., Chen G.H., Chen Y.H., Liao W.L., Liu C.Y., Chang K.P., et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br. J. Cancer 2009, 100:1002-1011.
21. Liu N., Chen N.Y., Cui R.X., Li W.F., Li Y., Wei R.R., et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012, 13:633-641.
22. Sengupta S., den Boon J.A., Chen I.H., Newton M.A., Stanhope S.A., Cheng Y.J., et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc. Natl. Acad. Sci. USA 2008, 105:5874-5878.
23. Zheng F., Liao Y.J., Cai M.Y., Liu Y.H., Liu T.H., Chen S.P., et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012, 61:278-289.
24. Remmele W., Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8:138-140.
25. Zlobec I., Steele R., Terracciano L., Jass J.R., Lugli A. Selecting immunohistochemical cut-off scores for novelbiomarkers of progression and survival in colorectal cancer. J. Clin. Pathol. 2007, 60:1112-1116.
26. Xiong Y., Fang J.H., Yun J.P., Yang J., Zhang Y., Jia W.H., et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
27. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68:425-433.
28. Lee J.W., Choi C.H., Choi J.J., Park Y.A., Kim S.J., Hwang S.Y., et al. Altered MicroRNA expression in cervical carcinomas. Clin. Cancer Res. 2008, 14:2535-2542.
29. Hamano R., Miyata H., Yamasaki M., Kurokawa Y., Hara J., Moon J., et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin. Cancer Res. 2011, 17:3029-3038.
30. Galluzzi L., Morselli E., Vitale I., Kepp O., Senovilla L., Criollo A., et al. MiR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70:1793-1803.
31. Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008, 68:10307-10314.
32. Pogribny I.P., Filkowski J.N., Tryndyak V.P., Golubov A., Shpyleva S.I., Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer 2010, 127:1785-1794.
33. Zhu Y., Yu F., Jiao Y., Feng J., Tang W., Yao H., et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin. Cancer Res. 2011, 17:7105-7115.
34. Garzon R., Heaphy C.E., Havelange V., Fabbri M., Volinia S., Tsao T., et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
35. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
36. Yip K.W., Reed J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406.
37. Lessene G., Czabotar P.E., Colman P.M. Bcl-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 2008, 7:989-1000.